Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech begins phase I lymphoma trial
The study is an open label, phase I study that is evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas who have failed prior standard therapy. The
The study is an open label, phase I study that is evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas who have failed prior standard therapy. The
The trial is based on promising clinical data from a previously conducted phase I/II clinical trial and is expected to enroll about 600 patients at 30-50 sites throughout
Patients in the study were randomized to receive either Acclaim, a proprietary combination of isosorbide mononitrate plus L-arginine, or conventional standard of care – nitrate alone therapy. Both
The National Institutes of Health (NIH) grant was made under the National Institute for Allergy and Infectious Disease (NIAID) program entitled “cooperative research for the development of vaccines,
Net loss for the 2004 fourth quarter was $1,764.3 million compared with net income of $335.3 million in the prior year. The 2004 fourth quarter included a charge
The guidelines state that Valcyte (valganciclovir) is the preferred treatment for patients with peripheral lesions that are not immediately sight-threatening. Authors cite ease of administration and lack of
The study found that 85% of Crohn’s patients who had experienced a reduced or loss of response to Remicade (infliximab) – currently the only FDA-approved biologic treatment for
The treatment approach, discovered by scientists at the University of Manitoba and the University of Ottawa, reduces cholesterol and triglycerides by acting on newly discovered targets in the
The first study of CX717 in the US will be a double-blind, placebo-controlled study using positron emission tomography (PET) imaging to determine the response of patients with Alzheimer’s
Under the terms of the agreement, Flamel will receive a cash payment from BMS, as well as recovering rights to data produced in connection with the collaboration, including